Meta-analysis of clinical outcomes of intravenous recombinant tissue plasminogen activator for acute ischemic stroke: Within 3 hours versus 3-4.5 hours

Current Medical Research and Opinion

Volumn 29, Issue 9, 2013, Pages 1105-1114

  Li, Bing Hu ^a   Ding, Xin ^b   Yin, Yan Wei ^a   Liu, Yun ^a   Gao, Chang Yue ^a   Zhang, Li Li ^a   Li, Jing Cheng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b General Hospital of PLA Chengdu Military Area Command   (China)

Author keywords

Acute ischemic stroke; Meta analysis; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DATA BASE; DRUG EFFICACY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RANKIN SCALE; STROKE PATIENT; SYMPTOM; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, INTRAVENOUS; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; PLASMINOGEN ACTIVATORS; PUBMED; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; STROKE; TIME FACTORS;

EID: 84882808439     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.818533     Document Type: Article

References (29)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: Heart disease and stroke statistics - 2010 update: A report from the American Heart Association. Circulation 2010;121:948-54
2. European Stroke Organisation Executive C, Committee ESOW. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507
3. van den Berg JS, de Jong G. Why ischemic stroke patients do not receive thrombolytic treatment: Results from a general hospital. Acta Neurol Scand 2009;120:157-60
4. Qureshi AI, Suri MF, Nasar A, et al. Thrombolysis for ischemic stroke in the United States: Data from National Hospital Discharge Survey 1999-2001. Neurosurgery 2005;57:647-54; discussion 47-54
5. Katzan IL, Hammer MD, Hixson ED, et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004;61:346-50
6. Albers GW, Olivot JM. Intravenous alteplase for ischaemic stroke. Lancet 2007;369:249-50
7. Hills NK, Johnston SC. Why are eligible thrombolysis candidates left untreated? Am J Prev Med 2006;31(6 Suppl 2):S210-16
8. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25
9. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51
10. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282: 2019-26
11. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29
12. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74
13. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: A metaanalysis. Stroke 2009;40:2438-41
14. Ahmed N, Wahlgren N, Grond M, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: An updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-74
15. Alias M, Staff I, McCullough LD. Early experience with community implementation of thrombolysis three to 4.5 hours after acute ischemic stroke. Connecticut Med 2011;75:531-6
16. Sarikaya H, Fischer A, Valko PO, et al. CT-based intravenous thrombolysis 3- 4.5 hours after acute ischemic stroke in clinical practice. Neurol Res 2011;33:701-7
17. Shobha N, Buchan AM, Hill MD; Canadian Alteplase for Stroke Effectiveness S. Thrombolysis at 3-4.5 hours after acute ischemic stroke onset - evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Cerebrovasc Dis 2011;31:223-8
18. Tekle WG, Chaudhry SA, Fatima Z, et al. Intravenous thrombolysis in expanded time window (3-4.5 hours) in general practice with concurrent availability of endovascular treatment. J Vasc Intervent Neurol 2012;5:22-6
19. Uyttenboogaart M, Stewart RE, Vroomen PC, et al. Utility of the strokethrombolytic predictive instrument. J Neurol Neurosurg Psychiatry 2008;79: 1079-81
20. Uyttenboogaart M, Vroomen PC, Stewart RE, et al. Safety of routine IV thrombolysis between 3 and 4.5 h after ischemic stroke. J Neurol Sci 2007;254:28-32
21. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): An observational study. Lancet 2008;372:1303-9
22. Larrue V, von Kummer RR, Muller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-41
23. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58
24. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29
25. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34
26. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7
27. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: A meta-analysis of safety data. Stroke 2003;34:2847-50
28. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375: 1695-703
29. Qureshi AI, Kirmani JF, Sayed MA, et al. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology 2005;64:2115-20